The EU Malaria Fund is a public-private partnership between the European Union, International Organizations, corporations, and organized civic society, providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally. It has been initiated by kENUP Foundation.
The EU Malaria works with a portfolio of 30 promising projects, including three secondary exploitations into COVID-19. Those originate from technology transfer out of many of Europe’s leading research organizations, and are not yet invested in by a large pharmaceutical company.
The Fund provides venture loans bearing interest to leading corporations active in the field - which is reflecting the high risk of the underlying portfolio - but no obligation to pay back the loan in case of failure of the respective project.